

### Clinical Pharmacy Program Guideline for Mepron

Program	Prior Authorization
Medication	Mepron® (atovaquone)
Pharmacy & Therapeutics Approval Date	11/2016
Effective Date	1/2017

**1. Background:**

**A. FDA Approved Indications**

1. **Prevention of *Pneumocystis jirovecii* pneumonia (PCP)** in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX). (NOTE: The taxonomy of *Pneumocystis* has changed. *P. carinii* only refers to infections found in rodents. *P. jirovecii* is a distinct species only found in humans.)
2. **Acute oral treatment of mild-to-moderate PCP** in patients who are intolerant to TMP-SMX

**2. Coverage Criteria:**

<p><b>A. <u>Authorization Criteria</u></b></p> <ol style="list-style-type: none"> <li>1. <i>Pneumocystis jirovecii</i> pneumonia (PCP)             <ol style="list-style-type: none"> <li>a. <b>Mepron</b> will be approved based on <b><u>all</u></b> of the following criteria:                 <ol style="list-style-type: none"> <li>(1) The patient has a diagnosis (i.e. HIV) warranting PCP infection prophylaxis.</li> </ol> <p style="text-align: center;"><b>-AND-</b></p> <li>(2) The patient has a documented intolerance to TMP-SMX <i>and</i> dapsone.</li> </li></ol> <p style="text-align: center;"><b>-OR-</b></p> <li>b. <b>Mepron</b> will be approved based on <b><u>all</u></b> of the following criteria:                 <ol style="list-style-type: none"> <li>(1) The patient has a diagnosis of mild to moderate pneumonia caused by <i>P. jirovecii</i>.</li> </ol> <p style="text-align: center;"><b>-AND-</b></p> </li> </li></ol>
---

(2) The patient has a documented intolerance to TMP-SMX.

**Authorization will be issued for 12 months.**

**3. References:**

1. Mepron® Prescribing Information. GlaxoSmithKline, May 2008.
2. Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 2009;58 (No. RR-4): 6-10.
3. Atovaquone. Facts and Comparisons. Web. 26 July 2011.
4. El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of *Pneumocystis carinii* pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 1998;339:1889-1895.

Program	Program type - Mepron (atovaquone)
<b>Change Control</b>	
Date	Change
09/08/2011	New policy
09/06/2012	Annual Review
12/17/2015	Annual Review
10/2016	Annual review. Updated policy template.